Review Article
Oral Lesions and Lymphoproliferative Disorders

P. Castellarin,1 G. Pozzato,2 G. Tirelli,3 R. Di Lenarda,1 and M. Biasotto1

1 Department of Dental Science, University of Trieste, 34127 Trieste, Italy
2 Department of Haematology, University of Trieste, 34142 Trieste, Italy
3 Department of Otorhinolaryngology, Head and Neck Surgery, University of Trieste, 34127 Trieste, Italy

Correspondence should be addressed to M. Biasotto, m.biasotto@fmc.units.it

Received 20 April 2010; Revised 13 July 2010; Accepted 26 July 2010

Copyright © 2010 P. Castellarin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lymphoproliferative disorders are heterogeneous malignancy characterized by the expansion of a lymphoid clone more or less differentiated. At the level of the oral cavity, the lymphoproliferative disorder can occur in various ways, most commonly as lymphoid lesions with extranodal externalization, but sometimes, oral lesions may represent a localization of a disease spread. With regard to the primary localizations of lymphoproliferative disorders, a careful examination of the head and neck, oral, and oropharyngeal area is necessary in order to identify suspicious lesions, and their early detection results in a better prognosis for the patient. Numerous complications have been described and frequently found at oral level, due to pathology or different therapeutic strategies. These complications require precise diagnosis and measures to oral health care. In all this, oral pathologists, as well as dental practitioners, have a central role in the treatment and long-term monitoring of these patients.

1. Introduction

Under the name of lymphoproliferative disorders various disease patterns are included which are characterized by the expansion of a lymphoid clone more or less differentiated. The application in recent times, of immunological methods for determining the phenotype of many cell components, together with the acquisitions of cytogenetic and molecular biology, as well as clinical behavior, have helped to relatively define a wide range of diseases that may present a heterogeneous clinical and morphological picture. In fact, the last classification of lymphoproliferative disorders lists 40 types of lymphoproliferative syndromes to immunophenotype B and 23 to immunophenotype T [1]. At the level of the oral cavity, the lymphoproliferative disorder can occur in various ways, most commonly as lymphoid lesions with extranodal externalization, but sometimes, oral lesions may represent a localization of a disease spread [2]. Under the key research that sees lymphoproliferative disorders associated with injury or events at the oral cavity, the present paper proposes a comprehensive classification as listed in Table 1 and deeply described below.

2. Classification and Related Aspects of the Oral Pathologies Associated with Lymphoproliferative Disorders

2.1. Group 1: Primary Oral Lymphoproliferative Disorders Limited to the Oral Cavity that Will not Invade Other Body Districts. Primary extranodal involvement can be seen in 10% to 35% of cases of non-Hodgkin lymphomas. These locations include the gastrointestinal tract, skin, testicles, kidneys, and bones [3, 4]; the NHL of the central nervous system account for 1% of cases [5, 6]. Although the oral involvement of NHL is rare, they are the second most common oral malignant disease after oral squamous cell carcinoma [7, 8], constituting of 2.2% of all malignancies of the head-neck, 3.5% of intraoral malignancies, 5% of tumors of the salivary glands, and 2.5% of all cases of NHL [8]. Although every other site may be affected, Ring Waldayer is the most commonly involved [9]. The WHO system classifies NHL as indolent, aggressive, and highly aggressive. Indolent lymphoma accounts for 40% of all NHL with the most common type being follicular lymphoma; aggressive lymphoma accounts for approximately 50% of
cases and include diffuse large B-cell lymphoma and T-cell natural killer (NK) cell lymphoma; highly aggressive lymphoma includes EBV-associated Burkitt lymphoma and lymphoblastic lymphoma [10]. Even though each type of NHL can occur at the level of oral cavity, the most common types are large-cell lymphoma and lymphoma of small lymphocytes lymphoma; mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma, Burkitt’s lymphoma, and immunocytoma, immunoblastic lymphoma are also reported [8, 11, 12]. The most common signs and symptoms with which the NHL will have intraoral include tissue swelling, tooth loss, and paresthesia. The radiographic measurements can highlight widespread osteolysis with loss of lamina dura. Oral lesions may appear as exophytic neoplasms, erythematous, asymptomatic, often with superficial ulcerations secondary to chronic trauma [11] (Figure 1).

Hodgkin’s disease is a form of malignancy characterized by proliferation of neoplastic cells (Hodgkin and Reed-Sternberg cells) associated with a polymorphic cellular component (lymphocytes, histiocytes, eosinophils, neutrophils, and plasma cells), considered to be reactive [13]. From its initial description until the 1990s, the nature and lineage of the Reed-Sternberg cell and the inflammatory infiltrate that compromises Hodgkin disease were debated. The application of PCR technique revealed that Hodgkin and Reed-Sternberg cells were clonal B cells in 98% of the patients, leading to the change of the designation of Hodgkin disease into Hodgkin lymphoma (LH) in the WHO classification of lymphoid neoplasms [1]. Primary oral and oropharyngeal lesions are rare [14]. Since the Waldayer ring is commonly involved by NHL that sometimes shows cells of Reed-Sternberg cell-like, the diagnosis of LH is difficult, especially when there are only small biopsy specimens [15, 16]. The most common site involved is the ring of Waldayer followed by the lips [17], tongue base [18, 19], buccal mucosa [20, 21], and parotid gland [22, 23].

The oral manifestations by plasma cell tumors can occur in three different ways: as a consequence of the local manifestation of multiple myeloma, bone plasmacytoma as solitary, or as extramedullary plasmacytoma [24]. The primary manifestations of plasma cell neoplasms at the oral level are represented by solitary and extramedullary plasmacytoma.

The Plasmacytoma of bone can be considered a localized solitary myeloma (Figure 2). Solitary bone plasmacytoma is a malignant monoclonal gammapathy [25, 26]; it is a plasma cell cancer that occurs as a single osteolytic lesion without plasmacytosis of the bone marrow and that is capable of secreting monoclonal M protein [27, 28]. This disease accounts for 10% of all plasma cell tumors and can strike [25, 27, 28], although rarely, in the oral cavity, showing a predilection for the mandibular retromolar area [29]; its radiological appearance may have one of two patterns, as either an oval-shaped lytic image with destruction of the cortical bone, or as a hyperinsufflating lesion showing a convex bicornital bone [30].

Instead, the extramedullary plasmacytoma is a plasma cell tumor located separately from the bone marrow [31]; it is found in all parts of the body where this lymphoid tissue [32–38], in 90% of the extramedullary plasmacytoma, is present in the head and neck. Clinically [39–41], the plasmacytoma extraosseous is present as a sessile or pedunculated exophytic neoformation, circumscribed or infiltrative, ranging in color from red-purple to gray or yellow-white [42–50].

### Table 1: Classification of the oral pathologies associated with lymphoproliferative disorders (see text for details).

| Group | Primary disorder | Localization of the primary disorder | Secondary (a) or associated (b) disorder | Localization of the secondary or associated disorder |
|-------|------------------|-------------------------------------|----------------------------------------|-----------------------------------------------|
| 1     | Lymphoproliferative disorders | Oral cavity | None | — |
| 2     | Lymphoproliferative disorders | Oral cavity | Lymphoproliferative disorders (a) | Other body districts |
| 3     | Lymphoproliferative disorders | Other body districts | Lymphoproliferative disorders (a) | Oral cavity |
| 4     | Oral lesions | Oral cavity | Lymphoproliferative disorders (b) | Other body districts |
| 5     | Lymphoproliferative disorders | Other body districts | Oral lesions (a) | Oral cavity |
| 6     | Lymphoproliferative disorders | Other body districts | Oral lesions secondary to the treatment of the primary disorder | Oral cavity |
| 7     | AIDS | — | AIDS-related lymphoproliferative disorders | Oral cavity |

Oral lesions refer to all of the diseases excluding lymphoproliferative disorders.
Figure 1: Primary extranodal non-Hodgkin lymphoma: painless mass involving the left palate.

Figure 2: Plasmacytoma: axial noncontrast CT image at the level of left maxillary sinus demonstrates an expansile, destructive intraosseous lesion involving the left maxillary sinus.

Figure 3: Paraneoplastic pemphigus: multiple erosions affecting the marginal gingival.

are the initial sign of submission in 12% to 15% of cases of MM [53–55]. The oral features include facial, oral, and dental pain, numbness and paresthesia, swelling, soft tissue neoplasms [56], tooth mobility, bleeding, and deposit of amyloid substance especially on the tongue [57–60]. Other examples of oral lesions as first manifestation of lymphoproliferative disorders may be the infiltration of the oral mucosa by a B-cell chronic lymphocytic leukemia [61], the lymphomatous papulosis, a condition mucocutaneous applicant, self-limited, characterized by papular eruptions [62], and Mycosis fungoides, T-cell cutaneous lymphoma in which the involvement of the oral cavity is a rare event but well documented [63, 64].

2.3. Group 3: Primary Systemic Lymphoproliferative Disorders That May Eventually Invade Oral Cavity. In addition to entering into this category, the previously treated lymphoproliferative disorders, where the diagnosis of oral lymphoid malignancy was subsequent to an indication of their early sign, mentioned in this regard a clinical-pathological entity of which we have evidence in the literature for over a century of mycosis fungoides (MF), chronic lymphoproliferative disorder with predominantly cutaneous involvement characterized by the proliferation of T lymphocytes that in advanced stages of the disease can accumulate also in lymphoid organs, bone marrow, and peripheral blood (Sezary Syndrome) [13]. Involvement in oral MF is an occasional finding observed from 7.4% to 18% of patients undergoing necropsy [65, 66]. Despite these findings relatively frequent mucosal involvement in vivo is a rare event; there is no predisposition to sex; age of onset varies from 36 to 81 years, with an average of 61 years. Oral sites most frequently involved are the tongue, palate, gingiva, buccal mucosa, lips, and oropharynx. In almost all patients, the lesions skin prior to the mucosa over a period of time ranging from 7 months to 40 years [67].

2.4. Groups 4: Primary Oral Lesions (Excluding Lymphoproliferative Disorders) That Are Associated with Systemic Lymphoproliferative Disorders, That Is, Paraneoplastic Pemphigus. Here is a list of non-specific signs and symptoms present in association with lymphoproliferative disorders of the oral cavity: lymphadenopathy, trismus, erythema, epiphora, pain, swelling, facial asymmetry or swelling of buccal mucosa, sinusitis, increased lacrimation and abscesses of the lacrimal sac, diplopia, nasal obstructions, sepsis, fever, runny nose, prosthetic instability, headache, and paresthesia idiopathic epistaxis. Suspicion of malignancy usually develops only after these inflammatory symptoms have not responded to conventional treatment protocols, upon which more accurate evaluations are required. Although oral lymphomas are extremely rare [68, 69], they can occur earlier and be placed in the differential diagnosis with non-specific inflammatory processes. Moreover, the early recognition of these subtle cancers can decrease their morbidity [70].

Paraneoplastic pemphigus (PNP), or paraneoplastic autoimmune multiorgan syndrome is a rare autoimmune vesiculobullous disease first described by Anhalt et al. in 1990 in patients with occult malignancies [71, 72]. The PNP may have mucocutaneous and systemic manifestations. Erosive eye lesions, sinuses, oral cavity, the gastrointestinal system, and respiratory and genital epithelium could affect them. Clinically, lesions may occur as polymorphic, such as pemphigus, bullous pemphigoid, erythema multiforme, the graft-versus-host disease, and lichen planus [73–75] (Figure 3).

Dermatomyositis (DM) is a rare inflammatory microangiopathic disease that affects skeletal muscles, with clinical externalization as characteristics mucocutaneous manifestations.
Oral lesions in paraneoplastic DM (leucoerythroplasia and ulcerative lesions) have rarely been described in the literature [76–79]. The DM is totally resolved if the underlying disease is treated and the resurgence of DM expresses relapse of malignancy [76, 79].

In the literature, there are reports of a single case of multiple myeloma with first manifestation at the oral level under the clinical aspects of lichen planus, showing extensive and irregular erosions present at buccal mucosa, labial, palatal mucosa, and ventral tongue [80].

2.5. Group 5: Primary Lymphoproliferative Disorders That May Eventually Invade Oral Cavity Yielding Lesions (Excluding Lymphoproliferative Disorders). The literature contains many works that correlate the paraneoplastic pemphigus (PNP), a rare autoimmune vesiculobullous disease underlying a malignancy [71, 72], with typical oral lesions of lichen planus [81] or lichenoid reactions [82]. In the literature there are numerous works reported that associate mucous membrane pemphigoid (MMP) with malignancies, including lung cancer [83], pancreatic adenocarcinoma [84], gastric adenocarcinoma [85], and squamous cell carcinoma of the conjunctiva [86]. A literature review undertaken in 2010 revealed only two cases reported of MMP with oral manifestations associated to lymphoproliferative disorders: a B-cell lymphoma [87] and chronic lymphocytic leukemia [88]. It has been described in the literature that large amount of cases have connection between bullous pemphigoid (BP) and lymphoproliferative disorders such as chronic lymphocytic leukemia [89–91] and lymphoblastic lymphoma [92].

Necrotizing oral processes, although rare in the general population, can rapidly evolve in devastating stages in immunocompromised patients [93–96] and are often associated with periodontal disease. These are patients with lymphoproliferative disorders such as acute lymphoblastic leukemia, which developed necrotic processes at the level of the oral cavity not associated with typical ulcer-necrotizing periodontal diseases, but by bacteria in the oral cavity usually found as Pseudomonas aeruginosa. Patients with impaired lymphocyte function or reduced counts of neutrophils, due to lymphoproliferative disorders, have led to the acquisition of new infections and/or exacerbation or reactivation of latent infection (periapical periodontitis and herpes simplex). In many cases the clinical presentation of oral infections may be atypical when compared to those normally seen in healthy patients.

The origin of odontogenous infection of the pulp and periodontal is frequently observed in patients with lymphoproliferative disorders and should be suspected when orofacial pain, extensive dental restorations, and dental caries and periapical radiopacity occur [97, 98].

Oropharyngeal candidiasis is the most common fungal infection in cancer patients [99–101]. The candidiasis may present as pseudomembranous candidiasis, erythematous, hyperplastic, or angular cheilitis. The symptoms include general discomfort, dysgeusia, xerostomia, and mouth burn. Deep fungal infections should be suspected in patients with solitary ulcer that does not retreat. This group includes infections such as aspergillosis, histoplasmosis, and that by Zygomycetes, and the treatment requires aggressive treatment with intravenous azoles, amphotericin B, and echinocandins [102].

Primary infection or reactivation of herpes viruses is common in patients with lymphoproliferative disorders especially during the advanced stages of the disease. Infection with herpes simplex is most common in these patients; the reactivation of the Varicella-Zoster virus (VZV) is less common [103]. Epstein-Barr virus infection (EBV) is associated with oral hairy leucoplaikia, a very rare whitish lesion that occurs on the lingual lateral margins in myelosuppressive patients [104, 105]. Infection by Cytomegalovirus (CMV) can occur on any intraoral mucosal surface in the form of an ulcer-free character of specificity, which persists for weeks or months.

Because of thrombocytopenia in the course of lymphoproliferative disorders, intraoral bleeding is commonly observed, which is present with petechiae, bruising, and occasionally with the formation of hematomas (Figure 4).

2.6. Group 6: Oral Complications Due to Systemic Treatment for Lymphoproliferative Disorders (i.e., Chemotherapy, Radiotherapy, Autologous, or Allogeneic Bone Marrow Transplant)

Chemotherapy and Radiotherapy. In addition to what is included in this paper the oral infectious complications (bacterial, fungal, viral), previously treated on immunosuppression induced by lymphoproliferative disorder, and here remembered as a possible consequence of drug-induced immunodeficiency, will consider the common characteristic found in the course of oncohaematology treatment regimens. Patients with lymphoproliferative disorders who are treated with high doses of radiotherapy at the head and neck level, associated with aggressive chemotherapy regimens, are at greatest risk of developing oropharyngeal mucositis. Xerostomia is often present in patients with lymphoproliferative disorders treated with radiotherapy in the head and neck region due to damage of the major salivary glands, which are still included in the irradiation of tumors. As another long-term complication of radiation therapy for head and neck lymphomas in patients who underwent radiotherapy, we noticed the osteoradionecrotic maxillary bone as a result of permanent damage of the capillary bed of bone and osteocytes caused by radiation.
Autologous Transplantation. Oral complications are observed in 85% of cases of patients after autologous bone marrow transplantation (ABMT). These complications are due to the effects derived from ablative chemotherapy and radiotherapy. Infections occur during the period of severe marrow aplasia and may be secondary to the conditions of the oral cavity before the transplant. Patients treated for lymphoproliferative disorders are at increased risk of relapse of the primary disease so as to develop subsequent tumors both hematologic and nonhematologic in this regard we consider the oral squamous cell carcinoma as a second primary solid tumor after allogeneic transplant [107].

A variety of circulating autoantibodies can be found from 20% to 61% of patients undergoing autologous bone marrow transplant [108–111], and a number of these patients may demonstrate autoantibody-mediated diseases such as myasthenia gravis and autoimmune cytopenias [112] and some cases of oral diseases, such as oral vesiculobullous (pemphigus and pemphigoid) [113–116].

The Graft-versus-host disease (GVHD) is a multisystem immunologic reaction resulting from the action of immunocompetent cells transplanted from a donor to an immunodeficient host [117]. The recipients of allogeneic hematopoietic cell transplantation (allo-HTC) are at greater risk of developing the disease from acute and chronic graft versus host. The likelihood of developing GVHD depends on the type of conditioning regimen (ablative vs. totally reduced intensity regimens). GVHD in oral lesions, although infrequent, can be observed, and rarely require specific treatment. Chronic GVHD typically develops after the hundredth day, with an incidence ranging from 25% to 40% after allo-HCT [107,117] (Figure 5). The mouth is one of the locations most commonly affected by events such as lichenoid mucositis (including ulcers), pain, odynophagia, dysgeusia, hypofunction of the salivary glands, caries decayed teeth, and rarely sclerotic processes that lead to a hypomobility and a reduction in functionality [10,118].

Supportive Therapy. Bisphosphonates are drugs used in combination with chemotherapy in the treatment of hypercalcemia secondary to malignancy, lytic bone metastases and multiple myeloma [119–121]. Starting from 2003, an increasing number of cases that describe the correlation between osteonecrosis of the jaw (ONJ) and administration of intravenous bisphosphonates were published in the literature [122–131] (Figure 6).

2.7. Group 7: AIDS-Related Lymphoproliferative Disorders of the Oral Cavity. Approximately 10% of all cases of non-Hodgkin lymphomas in the United States and Europe are AIDS related [132–134]. Typically, AIDS-related NHL has a predilection for extranodal sites and appears in the head and neck, in 50-60% of cases [135–144]; they have an aggressive course and a poor prognosis [145–147]. In histopathology these lymphomas are B-cells derived and characterized by widespread growth, pleomorphism, high-grade morphology, frequent mitotic figures, and increased tendency to develop into necrosis [148–153]. Lymphomas of head and neck may involve the gingiva, palate, tongue, tonsils, nasopharynx, orbits, parotid glands, jaw breasts, soft tissues, and hypopharynx. These tumors are associated with severe immunosuppression and a poor response to chemotherapy.

3. Conclusions

Lymphoid neoplasms are heterogeneous malignant disorders of the lymphatic system characterized by uncontrolled proliferation of lymphoid cells or their precursors. With regard to the primary localizations of lymphoproliferative disorders, a careful examination of the head and neck, oral, and oropharyngeal area is necessary in order to identify suspicious lesions and their early detection. An early diagnosis may allow treatment at early stages of the disease, resulting in a better prognosis for the patient. Numerous complications have been described and frequently found at oral level, due to pathology or different therapeutic strategies. These complications require a precise diagnosis and measures to oral health care. Furthermore, the evaluation of patients after treatment for lymphoma is essential to prevent relapse and to recognize early any eventual secondary localizations.

In all this, oral pathologists, as well as dental practitioners, have a central role in the treatment and long term monitoring of these patients, having the opportunity and the duty to examine and make a diagnosis at the level of hard and soft tissue of the oral cavity.

References

[1] E. S. Jaffe, N. L. Harris, H. Stein, and P. G. Isaacson, “Classification of lymphoid neoplasms: the microscope as a tool for disease discovery,” Blood, vol. 112, no. 12, pp. 4384–4399, 2008.
[2] B. W. Neville, D. D. Damm, C. M. Allen, and J. E. Bouquot, *Oral & Maxillofacial Pathology*, WB Saunders, Philadelphia, PA, USA, 2nd edition, 2002.

[3] T. Anderson, B. A. Chabner, R. C. Young, et al., “Malignant lymphoma. I. The histology and staging of 473 patients at the National Cancer Institute,” *Cancer*, vol. 50, no. 12, pp. 2699–2707, 1982.

[4] J. E. Seymour, B. Solomon, M. M. Wolf, E. H. Januszewicz, A. Wirth, and H. M. Prince, “Primary large-cell non-Hodgkin’s lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors,” *Clinical Lymphoma*, vol. 2, no. 2, pp. 109–115, 2001.

[5] R. Woodman, K. Shin, and G. Pinoe, “Primary non-Hodgkin’s lymphoma of the brain. A review,” *Medicine*, vol. 64, no. 6, pp. 425–430, 1985.

[6] C. R. Freeman, C. Shustik, M.-L. Brisson, et al., “Primary malignant lymphoma of the central nervous system,” *Cancer*, vol. 58, no. 5, pp. 1106–1111, 1986.

[7] C. A. DePena, P. Van Tassel, and Y.-Y. Lee, “Lymphoma of the head and neck,” *Radiologic Clinics of North America*, vol. 28, no. 4, pp. 723–743, 1990.

[8] J. B. Epstein, J. D. Epstein, N. D. Le, and M. Gorsky, “Characteristics of oral and paroral malignant lymphoma: a population-based review of 361 cases,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, vol. 92, no. 5, pp. 519–525, 2001.

[9] G. E. Kaugars and J. C. Burns, “Non-Hodgkin’s lymphoma of the oral cavity associated with AIDS,” *Oral Surgery Oral Medicine and Oral Pathology*, vol. 67, no. 4, pp. 433–436, 1989.

[10] H. Mawardi, C. Cutler, and N. Treister, “Medical management update: non-Hodgkin lymphoma,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology*, vol. 107, no. 1, pp. e19–e33, 2009.

[11] R. I. F. van der Waal, P. C. Huijgens, P. van der Valk, and I. van der Waal, “Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index,” *International Journal of Oral and Maxillofacial Surgery*, vol. 34, no. 4, pp. 391–395, 2005.

[12] S. Kemp, G. Gallagher, S. Kabani, V. Noonan, and C. O’Hara, “Oral non-Hodgkin’s lymphoma: review of the literature and World Health Organization classification with reference to 40 cases,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology*, vol. 105, no. 2, pp. 194–201, 2008.

[13] G. Castoldi and V. Liso, *Malattie del Sangue e Degli Organi Ematopoietici*, McGraw-Hill, Milano, Italy, 5th edition, 2007.

[14] G. B. Todd and L. Michaels, “Hodgkin’s disease involving Waldeyer’s lymphoid ring,” *Cancer*, vol. 34, no. 5, pp. 1769–1778, 1974.

[15] G. S. Pinkus, P. Thomas, and J. W. Said, “Leu-M1, a marker for Reed-Sternberg cells in Hodgkin’s disease. An immunoperoxidase study of paraffin-embedded tissues,” *American Journal of Pathology*, vol. 119, no. 2, pp. 244–252, 1983.

[16] H. Stein, J. Gerdes, and U. Schwab, “Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly-detected small-cell population,” *International Journal of Cancer*, vol. 30, no. 4, pp. 445–459, 1982.

[17] H. P. Cook, “Oral lymphomas,” *Oral Surgery, Oral Medicine, Oral Pathology*, vol. 14, no. 6, pp. 690–704, 1961.

[18] B. J. Bailey and P. C. Brindley, “Manifestations of malignant lymphomas in the head and neck,” *Transactions of American Academy of Ophthalmology and Otolaryngology*, vol. 74, no. 2, pp. 283–290, 1970.

[19] K. Terplan, “Über die intestinale form der lymphogranulomatose,” *Virchows Archiv*, vol. 237, no. 1-2, pp. 241–264, 1922.

[20] P. J. Bathard-Smith, H. S. Coonar, and A. F. Markus, “Hodgkin’s disease presenting intra-orally,” *British Journal of Oral Surgery*, vol. 16, no. 1, pp. 64–69, 1978.

[21] B. Meyer, B. Roswit, and S. M. Unger, “Hodgkin’s disease of the oral cavity,” *Journal of Roentgenology*, vol. 81, pp. 430–432, 1959.

[22] G. Dulci and F. Di Blasi, “On a case of pseudotumor of the parotid-Hodgkin’s disease localized in intraparotid lymphatic tissue,” *Annali di Stomatologia*, vol. 13, pp. 447–455, 1964.

[23] H. Glinski and M. Pawlicki, “Hodgkin’s disease with rare localization,” *Nowotwory*, vol. 22, no. 1, pp. 63–68, 1972.

[24] E. Marzetti, A. Marzetti, O. Palma, and R. W. Pizzuto, “Plasmacytomas of the head and neck,” *Acta Otorhinolaryngologica Italica*, vol. 16, no. 1, pp. 6–15, 1996.

[25] J. Bladé, “Mieloma múltiple y gamma patía monoclonal idiopática. Diagnóstico, pronóstico y tratamiento,” *Medicina Clinica*, vol. 90, pp. 704–714, 1988.

[26] J. D. Sánchez-Lépez, A. Martínez Plaza, and A. Marcos Vivas, “Mieloma solitario de presentación mandibular. Diagnóstico y tratamiento,” *Archivos de Odontostomatología*, vol. 15, pp. 95–98, 1999.

[27] A. Rollin-Mayordomo, F. Manso-García, J. M. Oliveras-Moreno, A. Restoy-Lozano, and C. Salazar-Fernández, “Plasmocitoma de huesos faciales: revisión de 3 casos,” *Revista Española de Cirugía Oral y Maxilofacial*, vol. 15, pp. 169–175, 1993.

[28] H. S. Loh, “A retrospective evaluation of 23 reported cases of solitary plasmacytoma of the mandible, with an additional case report,” *British Journal of Oral and Maxillofacial Surgery*, vol. 22, no. 3, pp. 216–224, 1984.

[29] J. S. Schreiman, R. A. McLeod, R. A. Kyle, and J. W. Beabout, “Multiple myeloma: evaluation by CT,” *Radiology*, vol. 154, no. 2, pp. 483–486, 1985.

[30] R. A. Kyle, “Multiple myeloma. Review of 869 cases,” *Mayo Clinic Proceedings*, vol. 50, no. 1, pp. 29–40, 1975.

[31] A. R. Ahmed, M. M. Avram, L. M. Duncan, et al., “A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions,” *The New England Journal of Medicine*, vol. 349, pp. 382–391, 2003.

[32] J. Cangiarella, J. Waisman, J.-M. Cohen, D. Chhieng, W. F. Symmans, and A. Goldenberg, “Plasmacytoma of the breast: a report of two cases diagnosed by aspiration biopsy,” *Acta Cytologica*, vol. 44, no. 1, pp. 91–94, 2000.

[33] M. Ganesh, N. S. Sankar, and R. Jagannathan, “Extramedullary plasmacytoma presenting as upper back pain,” *Journal of The Royal Society for the Promotion of Health*, vol. 120, no. 4, pp. 262–265, 2000.

[34] J. Wang, H. S. Pandha, J. Treleaven, and R. Powles, “Metastatic extramedullary plasmacytoma of the lung,” *Leukemia and Lymphoma*, vol. 35, no. 3–4, pp. 423–425, 1999.

[35] D. Gianom, M. Famos, D. Marugg, and M. Oberholzer, “Primary extramedullary plasmacytoma of the duodenum,” *Swiss Surgery*, vol. 5, no. 1, pp. 6–10, 1999.

[36] M. S. Panosian and J. K. Roberts, “Plasmacytoma of the middle ear and mastoid,” *American Journal of Otolaryngology*, vol. 15, no. 2, pp. 264–267, 1994.
H. Hidaka, K. Ikeda, T. Oshima, H. Ohtani, H. Suzuki, and E. Ascari, G. Merlini, and A. Riccardi, “Il mieloma multiplo,” Y. Rakover, M. Bennett, R. David, and G. Rosen, “Isolated A. Uceda-Monta˜n´es, G. Blanco, M. A. Saornil, C. Gonzalez, S. E. Sulzner, R. J. Amdur, and D. J. Weider, “Extramedullary plasmacytoma of the nasal fossa and extramedullary plasmocytoma of the nasal septum,” T. Takasaka, “A case of extramedullary plasmacytoma arising from the nasal septum,” Journal of Laryngology and Otology, vol. 114, no. 1, pp. 71–75, 2000.

M. Bangerter, A. Hildebrand, O. Waidmann, and M. Conde-Jimenez, and A. Jurado-Ramos, “Medio-facial degloving in extramedullary plasmacytoma with orbital invasion,” Acta Otorrinolaringologica Espanola, vol. 51, no. 1, pp. 71–75, 2000.

Y. Rakover, M. Bennett, R. David, and G. Rosen, “Isolated extramedullary Med Oral 2003;8:269–80. Neoplasia células plasmáticas/Plasma cell neoplasia 280 plasmacytoma of the true vocal fold,” The Journal of Laryngology & Otology, vol. 114, pp. 540–542, 2000.

A. Fernández-Pérez and A. Fernández-Sánchez, “Solitary extramedullary plasmocytoma of the nasal cavity,” Acta Otorrinolaringologica Espanola, vol. 40, no. 5, pp. 391–393, 1989.

M. Bangert, A. Hildebrand, O. Waidmann, and M. Grieshammer, “Fine needle aspiration cytology in extramedullary plasmacytoma,” Acta Cytologica, vol. 44, no. 3, pp. 287–291, 2000.

J. C. Casado-Morente, V. Povedano-Rodriguez, D. Piedrola-Maroto, M. Conde-Jimenez, and A. Jurado-Ramos, “Medio-facial degloving in extramedullary plasmacytoma with orbital invasion,” Acta Otorrinolaringologica Espanola, vol. 51, no. 1, pp. 71–75, 2000.

Y. Kabagia, D. Tamiolakis, M. Lambropoulou, A. Kakagia, A. Grekou, and N. Papadopoulos, “Systemic B-cell chronic lymphocytic leukemia first presenting as a cutaneous infiltrate arising at the site of a herpes simplex scar,” Minerva Stomatologica, vol. 54, no. 3, pp. 161–163, 2005.

W. L. Macaulay, “Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign—histologically malignant,” Archives of Dermatology, vol. 97, no. 1, pp. 23–30, 1968.

C. Allabert, E. Estève, P. Joly et al., “Mucosal involvement in lymphomatoid papulosis: four cases,” Annales de Dermatologie et de Venereologie, vol. 135, no. 4, pp. 273–278, 2008.

E. Gomez-De La Fuente, J. L. Rodriguez-Peralto, P. L. Ortiz, N. Barrientos, F. Vanaclocha, and L. Iglesias, “Oral involve-ment in mycosis fungoides: report of two cases and a literature review,” Acta Dermato-Venereologica, vol. 80, no. 4, pp. 299–301, 2000.

J. C. Long and M. C. Mihm, “Mycosis fungoides with extracutaneous dissemination: a distinct clinicopathologic entity,” Cancer, vol. 34, no. 5, pp. 1745–1755, 1974.

E. H. Epstein Jr., D. L. Levin, J. D. Croft Jr., and M. A. Lutzner, “Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings,” Medicine, vol. 51, no. 1, pp. 61–72, 1972.

D. Damm, D. K. White, M. L. Cibull, J. Drummond, and J. R. Cramer, “Mycosis fungoides: initial diagnosis via palatal biopsy with discussion of diagnostic advantages of plastic embedding,” Oral Surgery Oral Medicine and Oral Pathology, vol. 58, no. 4, pp. 413–419, 1984.

S. B. Kapadia, U. Desai, and V. S. Cheng, “Extramedullary plasmacytoma of the head and neck. A clinicopathologic study of 20 cases,” Medicine, vol. 61, no. 5, pp. 317–329, 1982.

B. D. Birt, “The management of malignant tracheal neoplasms,” Journal of Laryngology and Otology, vol. 84, no. 7, pp. 723–731, 1970.
[70] R. P. Rog, “Beware of malignant lymphoma masquerading as facial inflammatory processes,” Oral Surgery Oral Medicine and Oral Pathology, vol. 71, no. 4, pp. 415–419, 1991.

[71] G. J. Anhalt, S. C. Kim, J. R. Stanley et al., “Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia,” The New England Journal of Medicine, vol. 323, no. 25, pp. 1729–1735, 1990.

[72] J. E. Lane, C. Woody, L. S. Davis, M. F. Guil, and R. S. Jerath, “Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature,” Pediatrics, vol. 114, no. 4, pp. e513–e516, 2004.

[73] H. C. Nousari, R. Deterding, H. Wojtczak et al., “The mechanism of respiratory failure in paraneoplastic pemphigus,” The New England Journal of Medicine, vol. 340, no. 18, pp. 1406–1410, 1999.

[74] J. Wang, X. Zhu, R. Li et al., “Paraneoplastic pemphigus associated with castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China,” Archives of Dermatology, vol. 141, no. 10, pp. 1285–1293, 2005.

[75] V. T. Nguyen, A. Ndoye, K. D. Bassler et al., “Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus,” Archives of Dermatology, vol. 137, no. 2, pp. 193–206, 2001.

[76] C. M. Healy, A.-M. Tobin, B. Kirby, and S. R. Flint, “Oral lesions as an initial manifestation of dermatomyositis with occult malignancy,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 101, no. 2, pp. 184–187, 2006.

[77] A. Seno, M. Tokuda, H. Yamasaki, and K. Akiyama, “A case of amyopathic dermatomyositis presenting blister and oral ulcer,” Ryumachi, vol. 39, no. 6, pp. 836–840, 1999.

[78] S. Agbo-Godeau and J. C. Bertrand, “Lip ulceration in paraneoplastic pemphigus: a report of three cases including one long-term survivor,” Clinical and Experimental Dermatology, vol. 70, no. 4, pp. 587–589, 2000.

[79] J. P. Ortonne, “A study of nineteen immunocompromised patients with dermatomyositis,” Journal of the American Academy of Dermatology, vol. 6, no. 2, pp. 253–259, 1982.

[80] J. R. Bowden, C. Scully, J. W. Eveson, S. Flint, R. R. M. Harman, and S. K. Jones, “Multiple myeloma and bullous lichenoid lesions: an unusual association,” Oral Surgery Oral Medicine and Oral Pathology, vol. 70, no. 5, pp. 587–589, 1990.

[81] C. A. Parra, G. López González, and N. Pizzi de Parra, “Bullous pemphigoid and lymphoblastic lymphoma,” Medicina Cutanea Ibero-Latino-Americana, vol. 7, no. 1–3, pp. 51–54, 1979.

[82] A. C. Jones, M. L. Gulley, and P. D. Freedman, “Necrotizing ulcerative stomatitis in human immunodeficiency virus-seropositive individuals: a review of the histopathologic, immunohistochemical, and virologic characteristics of 18 cases,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 89, no. 3, pp. 323–332, 2000.

[83] D. W. Eisele, A. F. Inglis Jr., and M. A. Richardson, “Noma and noma neonatorum,” Ear, Nose and Throat Journal, vol. 69, no. 2, pp. 119–120, 122–123, 1990.

[84] P. El Baze, A. Thys, H. Vinti, A. Deville, P. Dellamonica, and J.-P. Ortonne, “A study of nineteen immunocompromised patients with extensive skin lesions caused by Pseudomonas aeruginosa with and without bacteremia,” Acta Dermato-Venereologica, vol. 71, no. 5, pp. 411–415, 1991.

[85] K. Uchiyama, Y. Yamamoto, K. Taniuchi, C. Matsu, Y. Fushida, and Y. Shirao, “Remission of antiepileptic (laminin-5) cicatrical pemphigoid after excision of gastric carcinoma,” Cornea, vol. 19, no. 4, pp. 564–566, 2000.

[86] V. Sivalingam, C. L. Shields, J. A. Shields, and J. D. Pearah, “Squamous cell carcinoma of the conjunctiva associated with benign mucous membrane pemphigoid,” Annals of Ophthalmology, vol. 22, no. 3, pp. 106–109, 1990.

[87] J.-C. Bystryn, E. Hodak, S.-Q. Gao, J. V. Chuba, and E. L. Amorosi, “A paraneoplastic mixed bullous skin disease associated with anti-skin antibodies and a B-cell lymphoma,” Archives of Dermatology, vol. 129, no. 7, pp. 870–875, 1993.

[88] R. K. Seth, G. W. Su, and S. C. Pflugfelder, “Mucous membrane pemphigoid in a patient with chronic lymphocytic leukemia,” Cornea, vol. 23, no. 7, pp. 740–743, 2004.

[89] L. J. Cuni, H. Grüenwald, and F. Rosner, “Bullous pemphigoid in chronic lymphocytic leukemia with the demonstration of antibasement membrane antibodies,” American Journal of Medicine, vol. 57, no. 6, pp. 987–992, 1974.

[90] L. T. Goodnough and W. A. Muir, “Bullous pemphigoid as a manifestation of chronic lymphocytic leukemia,” Archives of Internal Medicine, vol. 140, no. 11, pp. 1526–1527, 1980.

[91] L. Misery, F. Cambazard, R. Rimokh et al., “Bullous pemphigoid associated with chronic B-cell lymphatic leukaemia: the anti-230-kDa autoantibody is not synthesized by leukemic cells,” British Journal of Dermatology, vol. 141, no. 1, pp. 155–157, 1999.

[92] C. A. Parra, G. López González, and N. Pizzi de Parra, “Bullous pemphigoid and lymphoblastic lymphoma,” Medicina Cutanea Ibero-Latino-Americana, vol. 7, no. 1–3, pp. 51–54, 1979.

[93] A. C. Jones, M. L. Gulley, and P. D. Freedman, “Necrotizing ulcerative stomatitis in human immunodeficiency virus-seropositive individuals: a review of the histopathologic, immunohistochemical, and virologic characteristics of 18 cases,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 89, no. 3, pp. 323–332, 2000.
[100] J. B. Epstein, M. Gorsky, P. Hancock, N. Peters, and C. H. Sherlock, “The prevalence of herpes simplex virus shedding and infection in the oral cavity of seropositive patients undergoing head and neck radiation therapy,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, vol. 94, no. 6, pp. 712–716, 2002.

[101] A. N. Davies, K. Broadley, and D. Brightton, “Salivary gland hypofunction in patients with advanced cancer,” *Oral Oncology*, vol. 38, no. 7, pp. 680–685, 2002.

[102] A. Böhme and M. Karthaus, “Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium,” *Chemotherapy*, vol. 45, no. 5, pp. 315–324, 1999.

[103] M. Bocek, H. W. Kim, M. E. D. Flowers, J. D. Meyers, and R. A. Bowden, “Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study,” *Blood*, vol. 107, no. 5, pp. 1800–1805, 2006.

[104] M. A. Lerman, J. Laudench, F. M. Marty, L. R. Baden, and N. S. Treister, “Management of oral infections in cancer patients,” *Dental Clinics of North America*, vol. 52, no. 1, pp. 129–153, 2008.

[105] J. B. Epstein, C. H. Sherlock, and J. S. Greenspan, “Hairy leukoplakia-like lesions following bone-marrow transplantation,” *AIDS*, vol. 5, no. 1, pp. 101–102, 1991.

[106] M. Bassal, A. C. Mertens, L. Taylor et al., “Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the childhood cancer survivor study,” *Journal of Clinical Oncology*, vol. 24, no. 3, pp. 476–483, 2006.

[107] F. Demarosi, C. Bez, A. Sardella, G. Lodi, and A. Carassi, “Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation,” *Archives of Dermatology*, vol. 138, no. 6, pp. 842–843, 2002.

[108] J. Lister, H. Messner, E. Keystone, R. Miller, and M. J. Fritzler, “Autoantibody analysis of patients with graft versus host disease,” *Journal of Clinical and Laboratory Immunology*, vol. 24, no. 1, pp. 19–23, 1987.

[109] A. M. Rouquette-Gally, D. Boyeldieu, A. C. Prost, and E. Gluckman, “Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term surviving patients,” *Transplantation*, vol. 46, no. 2, pp. 238–240, 1988.

[110] C. I. E. Smith, L. Hammarström, and A.-K. Leffert, “Bone-marrow grafting induces acetylcholine receptor antibody formation,” *The Lancet*, vol. 1, no. 8435, p. 978, 1985.

[111] C. I. E. Smith, R. Norberg, G. Möller, B. Lönnqvist, and L. Hammarström, “Autoantibody formation after bone marrow transplantation. Comparison between acetylcholine receptor antibodies and other autoantibodies and analysis of HLA and Gm markers,” *European Journal of Immunology*, vol. 29, no. 3, pp. 128–134, 1989.

[112] Y. Sherer and Y. Shoenfeld, “Autoimmune diseases and autoimmunity post-bone marrow transplantation,” *Bone Marrow Transplantation*, vol. 22, no. 9, pp. 873–881, 1998.

[113] A. L. Herr, A. Hatami, V. Kokta, J. H. Dalle, M. A. Champagne, and M. Duval, “Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation,” *Bone Marrow Transplantation*, vol. 35, no. 4, pp. 427–428, 2005.

[114] P. Szabolcs, M. Reese, K. B. Yancey, R. P. Hall, and J. Kurtzberg, “Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease,” *Bone Marrow Transplantation*, vol. 34, no. 5, pp. 327–329, 2002.

[115] C. Delbvaldo, L. Rieckhoff-Cantoni, C. Helg, and J.-H. Saurat, “Bullous pemphigoid associated with acute graft-versus-host disease after allogeneic bone marrow transplantation,” *Bone Marrow Transplantation*, vol. 10, no. 4, pp. 377–379, 1992.

[116] J. Burger, J. Gmür, and L. Bruckner-Tuderman, “Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation?” *Bone Marrow Transplantation*, vol. 9, no. 2, pp. 139–141, 1992.

[117] T. I. Eggleston, V. B. Ziccardi, and H. Lumerman, “Graft-versus-host disease: case report and discussion,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, vol. 86, no. 6, pp. 692–696, 1998.

[118] M. M. Schubert and M. E. P. Correa, “Bone marrow-versus-host disease,” *Dental Clinics of North America*, vol. 52, no. 1, pp. 79–109, 2008.

[119] S. Dhillon and K. A. Lyseng-Williamson, “Zoledronic acid: a review of its use in the management of bone metastases of malignancy,” *Drugs*, vol. 68, no. 4, pp. 507–534, 2008.

[120] A. Lipton, “Treatment of bone metastases and bone pain with bisphosphonates,” *Supportive Cancer Therapy*, vol. 4, no. 2, pp. 92–100, 2007.

[121] F. Saad, D. M. Gleason, R. Murray et al., “Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer,” *Journal of the National Cancer Institute*, vol. 96, no. 11, pp. 879–882, 2004.

[122] R. E. Marx, “Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic,” *Journal of Oral and Maxillofacial Surgery*, vol. 61, no. 9, pp. 1115–1117, 2003.

[123] M. Biasotto, S. Chiandussi, F. Dore et al., “Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws,” *Acta Odontologica Scandinavica*, vol. 64, no. 4, pp. 348–354, 2006.

[124] R. E. Coleman, “Risks and benefits of bisphosphonates,” *British Journal of Cancer*, vol. 98, no. 11, pp. 1736–1740, 2008.

[125] V. Adamo, N. Caristi, M. M. Saccà et al., “Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients,” *Expert Opinion on Pharmacotherapy*, vol. 9, no. 8, pp. 1351–1361, 2008.

[126] P. N. Sambrook and P. Ebeling, “Osteonecrosis of the jaw,” *Current Rheumatology Reports*, vol. 10, no. 2, pp. 97–101, 2008.

[127] D. G. Pendrys and S. L. Silverman, “Osteonecrosis of the jaws and bisphosphonates,” *Current Osteoporosis Reports*, vol. 6, no. 1, pp. 31–38, 2008.

[128] N. B. Watts and R. D. Marciani, “Osteonecrosis of the jaw,” *Southern Medical Journal*, vol. 101, no. 2, pp. 160–165, 2008.

[129] S.-B. Woo and J. R. Kalmar, “Osteonecrosis of the jaws and bisphosphonates,” *Alpha Omega*, vol. 100, no. 4, pp. 194–202, 2007.

[130] S. L. Ruggiero and S.-B. Woo, “Bisphosphonate-related osteonecrosis of the jaws,” *Dental Clinics of North America*, vol. 52, no. 1, pp. 111–128, 2008.

[131] Y. Sawatari and R. E. Marx, “Bisphosphonates and bisphosphonate-induced osteonecrosis,” *Oral and Maxillofacial Surgery Clinics of North America*, vol. 19, no. 4, pp. 487–498, 2007.

[132] L. Dal Maso, D. Serraino, and S. Franceschi, “Epidemiology of AIDS-related tumours in developed and developing countries,” *European Journal of Cancer*, vol. 37, no. 10, pp. 1188–1201, 2001.
